The prognostic role of NKG2A expression for patients with chronic myeloid leukemia after treatment discontinuation.

Xu, Ziyao; Yin, Jinyu; Sun, Qian; Hu, Jinhua; Hong, Ming; Qian, Sixuan; Liu, Wenjie

Xu, Ziyao; Yin, Jinyu; Sun, Qian; Hu, Jinhua; Hong, Ming; Qian, Sixuan; Liu, Wenjie.

Affiliation

Xu Z; Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.
Yin J; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, China.
Sun Q; Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.
Hu J; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, China.
Hong M; Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.
Qian S; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, China.
Liu W; Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.

Leuk Lymphoma ; 63(11): 2616-2626, 2022 Nov.

Article de En | MEDLINE | ID: mdl-35758278

Sujet(s)
Mots clés

Chronic myeloid leukemia (CML); NKG2A; NKG2D; natural killer (NK) cells; treatment-free remission (TFR); tyrosine kinase inhibitor (TKI)

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Leucémie myéloïde chronique BCR-ABL positive / Inhibiteurs de protéines kinases Type d'étude: Diagnostic_studies / Prognostic_studies Limites: Humans Langue: En Journal: Leuk Lymphoma Sujet du journal: HEMATOLOGIA / NEOPLASIAS Année: 2022 Type de document: Article Pays d'affiliation: Chine Pays de publication: États-Unis d'Amérique

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google